Samsung Medical Center – Developmental Therapeutics Review – Q4 2010

Date: November 1, 2010
Pages: 93
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: S642DA99191EN
Leaflet:

Download PDF Leaflet

Samsung Medical Center – Developmental Therapeutics Review – Q4 2010
Samsung Medical Center – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Samsung Medical Center – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope
  • Review of therapeutics under development by Samsung Medical Center.
  • Overview of products under development across various therapy areas.
  • Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Samsung Medical Center with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of Samsung Medical Center’s therapeutic products in the last quarter.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify new drug targets and therapeutic classes in Samsung Medical Center’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
  • Evaluate Samsung Medical Center’s position with total access to a detailed information on its therapeutic products development.
  • Assess the growth potential of Samsung Medical Center in its therapy areas of focus.
  • Exploit collaboration and partnership opportunities with Samsung Medical Center.
  • Avoid Intellectual Property Rights related issues.
Samsung Medical Center Snapshot
Samsung Medical Center Overview
Key Information
Key Facts
Samsung Medical Center – Research and Development Overview
Key Therapeutic Areas
Samsung Medical Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Samsung Medical Center – Pipeline Products Glance
Samsung Medical Center – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Samsung Medical Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Samsung Medical Center – Drug Profiles
Aprepitant + Ramosetron + Dexamethasone for Chemotherapy-Induced Nausea and Vomiting
  Product Description
  Mechanism of Action
  R&D Progress
Bevacizumab
  Product Description
  Mechanism of Action
  R&D Progress
Gemcitabine + Cisplatin
  Product Description
  Mechanism of Action
  R&D Progress
Gemcitabine + Oxaliplatin/Gemcitabine + Oxaliplatin + Erlotinib
  Product Description
  Mechanism of Action
  R&D Progress
Gemcitabine + Paclitaxel
  Product Description
  Mechanism of Action
  R&D Progress
Iressa + Alimta
  Product Description
  Mechanism of Action
  R&D Progress
Misoprostol
  Product Description
  Mechanism of Action
  R&D Progress
S-1 + Oxaliplatin
  Product Description
  Mechanism of Action
  R&D Progress
XP + Simvastatin
  Product Description
  Mechanism of Action
  R&D Progress
Alfuzosin
  Product Description
  Mechanism of Action
  R&D Progress
Aprepitant + Ramosetron + Dexamethasone
  Product Description
  Mechanism of Action
  R&D Progress
Capecitabine + Cisplatin
  Product Description
  Mechanism of Action
  R&D Progress
Capecitabine + Paclitaxel
  Product Description
  Mechanism of Action
  R&D Progress
CCRT with weekly docetaxel & cisplatin
  Product Description
  Mechanism of Action
  R&D Progress
Cisplatin + Etoposide + Ifosfamide + Dexamethasone
  Product Description
  Mechanism of Action
  R&D Progress
CreaVax-PC
  Product Description
  Mechanism of Action
  R&D Progress
Docetaxel + Cisplatin
  Product Description
  Mechanism of Action
  R&D Progress
Docetaxel + Oxaliplatin
  Product Description
  Mechanism of Action
  R&D Progress
Epirubicin + Cisplatin + Capecitabine
  Product Description
  Mechanism of Action
  R&D Progress
Fludarabine + Busulfan + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
FOLFIRI + Simvastatin
  Product Description
  Mechanism of Action
  R&D Progress
FOLFOX6 + Cetuximab
  Product Description
  Mechanism of Action
  R&D Progress
Gemcitabine + TS-1
  Product Description
  Mechanism of Action
  R&D Progress
L-Ascorbic Acid
  Product Description
  Mechanism of Action
  R&D Progress
MTX, MVD, VIA
  Product Description
  Mechanism of Action
  R&D Progress
Nilotinib
  Product Description
  Mechanism of Action
  R&D Progress
Oxaliplatin + S-1 + radiotherapy
  Product Description
  Mechanism of Action
  R&D Progress
Pazopanib
  Product Description
  Mechanism of Action
  R&D Progress
Pazopanib + Capecitabine + Oxaliplatin
  Product Description
  Mechanism of Action
  R&D Progress
RAD001 + Capecitabine
  Product Description
  Mechanism of Action
  R&D Progress
Rituximab
  Product Description
  Mechanism of Action
  R&D Progress
S-1 + Oxaliplatin + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Simvastatin
  Product Description
  Mechanism of Action
  R&D Progress
Simvastatin + Gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
Simvastatin + Irinotecan + Fluorouracil + Leucovorin
  Product Description
  Mechanism of Action
  R&D Progress
Sorafenib
  Product Description
  Mechanism of Action
  R&D Progress
Sorafenib_
  Product Description
  Mechanism of Action
  R&D Progress
Sunitinib_
  Product Description
  Mechanism of Action
  R&D Progress
Temozolomide
  Product Description
  Mechanism of Action
  R&D Progress
TS-1 + Oxaliplatin
  Product Description
  Mechanism of Action
  R&D Progress
Velcade + CHOP
  Product Description
  Mechanism of Action
  R&D Progress
Vorinostat + Gemtuzumab Ozogamicin + Idarubicin + Cytarabine
  Product Description
  Mechanism of Action
  R&D Progress
CPT-11
  Product Description
  Mechanism of Action
  R&D Progress
Irinotecan
  Product Description
  Mechanism of Action
  R&D Progress
Taxol + Everolimus
  Product Description
  Mechanism of Action
  R&D Progress
Triamcinolone Acetonide
  Product Description
  Mechanism of Action
  R&D Progress
TS-1 + Sorafenib
  Product Description
  Mechanism of Action
  R&D Progress
Samsung Medical Center – Pipeline Analysis
Samsung Medical Center – Pipeline Products by Therapeutic Class
Samsung Medical Center Pipeline Products By Target
Samsung Medical Center – Pipeline Products by Route of Administration
Samsung Medical Center – Pipeline Products by Molecule Type
Samsung Medical Center – Recent Pipeline Updates
Samsung Medical Center - Dormant Projects
Samsung Medical Center – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


LIST OF TABLES

Samsung Medical Center – Pipeline by Therapy Area and Indication, 2010
Samsung Medical Center – Pipeline by Stage of Development, 2010
Samsung Medical Center – Monotherapy Products in Pipeline, 2010
Samsung Medical Center – Combination Treatment Modalities in Pipeline, 2010
Samsung Medical Center – Phase III, 2010
Samsung Medical Center - Phase II, 2010
Samsung Medical Center - Phase I, 2010
Samsung Medical Center - Pipeline By Therapeutic Class, 2010
Samsung Medical Center - Pipeline By Target, 2010
Samsung Medical Center – Pipeline By Route of Administration, 2010
Samsung Medical Center – Pipeline By Molecule Type, 2010
Samsung Medical Center – Recent Pipeline Updates, 2010
Samsung Medical Center - Dormant Developmental Projects, 2010 90

LIST OF FIGURES

Samsung Medical Center – Pipeline by Therapy Area and Indication, 2010
Samsung Medical Center – Pipeline by Stage of Development, 2010
Samsung Medical Center – Monotherapy Products in Pipeline, 2010
Samsung Medical Center – Combination Treatment Modalities in Pipeline, 2010
Samsung Medical Center – Pipeline By Therapeutic Class, 2010
Samsung Medical Center - Pipeline By Target, 2010
Samsung Medical Center – Pipeline By Route of Administration, 2010
Samsung Medical Center – Pipeline By Molecule Type, 2010 88

Ask Your Question

Samsung Medical Center – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: